<DOC>
	<DOCNO>NCT01439347</DOCNO>
	<brief_summary>A phase 3 study treatment subject &gt; or= 60 year old newly diagnose acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>A Phase 3 Study Evaluate Marqibo® Treatment Subjects ≥ 60 Years Old With Newly Diagnosed ALL</brief_title>
	<detailed_description>A phase 3 , multicenter , randomize study evaluate substitution Marqibo® ( Vincristine Sulfate Liposomes Injection , VSLI ) standard Vincristine Sulfate Injection ( VSI ) induction , intensification , maintenance phase combination chemotherapy treatment subject &gt; or= 60 year old newly diagnose acute lymphoblastic leukemia ( ALL ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Have provide write , sign , date informed consent participate study , accordance ICH GCP Guideline E6 applicable local regulations.Are age &gt; or=60 year ( time provide informed consent ) . Have newly diagnose , histologically proven , untreated Philadelphia chromosomenegative ( Ph ) ALL , &gt; or= 5 % bone marrow blast . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Have life expectancy &gt; or= 3 month . Have renal liver function define within 14 day , inclusive , prior study enrollment , unless abnormality consider attributable leukemia : Total bilirubin ≤ 2.0 x upper limit normal ( ULN ) , unless subject know diagnosis Gilbert 's disease Aspartate transaminase ( AST , SGOT ) alanine transaminase ( ALT , SGPT ) ≤ 3 x ULN Serum creatinine ≤ 1.5 x ULN . Not major surgery within 4 week plan start treatment . If female , postmenopausal , surgically sterilize , willing use acceptable method birth control ( eg , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) screen visit 30 day last dose protocol define chemotherapeutic agent . If male sexually active partner childbearing potential , agree use acceptable barrier method contraception screen visit 30 day last dose protocol define chemotherapeutic agent . Have ability willingness fully comply study procedure restriction . Has prior systemic chemotherapy ( ALL malignancy ) . Has prior vincristine reason . Is plan undergo stem cell transplantation ( SCT ) part firstline therapy ALL . Has Burkitt 's lymphoma/leukemia . Has Philadelphia chromosomepositive ( Ph+ ) ALL and/or BCR/ABL rearrangement document fluorescent insitu hybridization ( FISH ) , cytogenetics , polymerase chain reaction ( PCR ) . Has active central nervous system ( CNS ) disease . Has ongoing neuropathy etiology &gt; Grade 1 . Has history persistent active neurologic disorder include demyelinate form CharcotMarieTooth syndrome , acquire demyelinate disorder , demyelinate condition . Prior hydroxyurea ( Hydrea® ) management condition leukocytosis prior hydroxyurea &gt; 7 day duration management leukocytosis ( hydroxyurea management leukocytosis must plan taper Day 5 Induction ) . Has receive prior steroid within 7 day begin protocolspecified Induction therapy reason leukocytosis ( steroids management leukocytosis allow must plan taper Day 5 Induction ) . Has active serious infection control oral IV antibiotic antifungal . Has receive investigational therapy within 28 day begin protocoldefined chemotherapeutic treatment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Marqibo</keyword>
	<keyword>HALLMARQ</keyword>
	<keyword>leukemia</keyword>
	<keyword>front-line</keyword>
	<keyword>ALL</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
</DOC>